Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from ...

(Reuters) - Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

It has been a tough period for Novo Nordisk shareholders. In the summer of 2024, the share price was over DKK 1,000 per share. Now it is approaching DKK 400.The latest dip comes on Wednesday morning ...

Riding on a surge in global demand for its patented obesity and diabetes medicines Ozempic, Wegovy and Rybelsus, ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...